ONC

BeOne Medicines Ltd. American Depositary Shares (ONC) | Rumor.io

BeOne Medicines

ONC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,042

Bullish sentiment (50-day avg)81%

Price to earnings ratio64.5

Market capitalization41.5B

Earnings per share5.69

Dividend yield (TTM)—

Revenue (annual)5.3B

Net income (annual)286.9M

Social

What share of all stock conversation is about ONC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 29

ONC's price cleared key resistance with expanding volume, and the RSI is rising, but a short-term overbought condition should be watched.
A healthy Golden Cross has formed as the 50DMA crosses the 200DMA, and the bias has turned bullish, with a rising MACD and momentum favoring higher targets.
Trendline support is intact, and the bullish bias remains until a close below the breakout pivot invalidates the move, with momentum expanding and higher volume spikes indicating a strong trend.

Generated by AI

Sentiment

Of the messages about ONC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	64.52% -29.93	80% -10.74
Bearish	0%	0% 0	35.48% +29.93	20% +10.74

Sep 2

$ONC has a market capitalization of $28M, which is considered undervalued compared to fintech comps trading at x20.
The accumulation of $ONC has been stacking up since the news drop, with bids increasing and a strong reversal in momentum.
$ONC has seen a strong reversal from a low point, indicating bullish momentum and a potential breakout setup, with the chart suggesting further increases.

Generated by AI

Topics

Of the messages about ONC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	97.47%	50.4%
Analysts	0%	0%	1.27%	3.96%
Technical Analysis	100%	100%	1.27%	3.5%
Earnings	0%	0%	0%	41.62%
Controversies	0%	0%	0%	0.53%
Macro	0%	0%	0%	0%

Sep 29

ONC's price cleared key resistance with expanding volume, and the RSI is rising, but the short-term overbought level should be watched.
A Golden Cross has formed as the 50DMA crosses the 200DMA, turning the bias bullish, and confirmation is expected on rising MACD.
The MACD has made a bullish cross, and the price is holding above trendline support, indicating momentum favors higher targets.

Generated by AI

Community

Of the messages about ONC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	74.29%	51.47%	55.6%
Newcomers	100%	25.71%	48.53%	44.4%

Sep 29

Newcomers are focusing on the potential entry point for ONC after a pullback to the breakout level, with a suggested stop loss to manage risk.
The golden cross formed as the 50DMA crossed the 200DMA, turning the bias bullish, and confirmation is expected on the rising MACD.
ONC's price cleared key resistance with expanding volume, and the RSI is rising, but it's essential to watch for short-term overbought signals.

Generated by AI

BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track record against a less clear-cut value case. BeOne Medicines is up 86.0% over three years, which makes the stock more dependent on whether the business can now justify that stronger share price profile. FDA...

24d agoYahoo Finance

The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal

BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination of first-in-class immunotherapy approval and U.S. tariff exemption tied to onshoring commitments reshapes BeOne’s positioning in cancer care and its cost base in a key...

25d agoYahoo! Finance Canada

BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?

BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing more than $1 billion of U.S. manufacturing investment, including a $300 […]

25d agoYahoo Finance

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more than 31,000 Americans a year. The approval rests on Phase 3 data showing patients lived a median of 26.4 months, more than two years, […]

28d agoYahoo Finance

Also Discussed

Investors talking about ONC also mention

#	Name	Attention
1	OP Bancorp Common StockOPBK	0%0
2	Forafric Global PLCAFRI	0%new
3	Fidelity Disruptive Communications ETFFDCF	0%0
4	Defiance AI & Power Infrastructure ETFAIPO	0%0
5	Revolution Medicines, Inc.RVMD	0.01%-0.01
6	SPDR Galaxy Transformative Tech Accelerators ETFTEKX	0%new
7	Democratic Large Cap Core ETFDEMZ	0%0
8	Summit Therapeutics Inc.SMMT	0.05%-0.04
9	Genmab A/S American Depositary SharesGMAB	0%0
10	Nuveen Nasdaq 100 Dynamic Overwrite FundQQQX	0%0

BeOne Medicines Ltd. American Depositary Shares

Healthcare
Biotechnology

BeOne Medicines Ltd. American Depositary Shares is the U.S.-traded ADR of BeOne Medicines Ltd., a global oncology company based in Switzerland. The business focuses on discovering and developing treatments for cancer, with activity spanning hematology and solid tumor medicines, as well as broader oncology research and commercialization efforts. Its portfolio includes prescription therapies and clinical-stage drug candidates designed to address a range of cancer types across major markets in the United States, Europe, China, and other international regions. Through its American Depositary Shares, BeOne Medicines provides U.S. investors with access to the company’s ordinary shares in a form that is commonly used for foreign issuers in U.S. markets. The asset reflects a biotechnology and pharmaceutical platform centered on oncology innovation, with operations supported by global development, regulatory, and commercial capabilities.

Website

Location

94 Aeschengraben 27

Basel, 4051

Switzerland

Social

What share of all stock conversation is about ONC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 29

ONC's price cleared key resistance with expanding volume, and the RSI is rising, but a short-term overbought condition should be watched.
A healthy Golden Cross has formed as the 50DMA crosses the 200DMA, and the bias has turned bullish, with a rising MACD and momentum favoring higher targets.
Trendline support is intact, and the bullish bias remains until a close below the breakout pivot invalidates the move, with momentum expanding and higher volume spikes indicating a strong trend.

Generated by AI

Sentiment

Of the messages about ONC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	64.52% -29.93	80% -10.74
Bearish	0%	0% 0	35.48% +29.93	20% +10.74

Sep 2

$ONC has a market capitalization of $28M, which is considered undervalued compared to fintech comps trading at x20.
The accumulation of $ONC has been stacking up since the news drop, with bids increasing and a strong reversal in momentum.
$ONC has seen a strong reversal from a low point, indicating bullish momentum and a potential breakout setup, with the chart suggesting further increases.

Generated by AI

Topics

Of the messages about ONC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	97.47%	50.4%
Analysts	0%	0%	1.27%	3.96%
Technical Analysis	100%	100%	1.27%	3.5%
Earnings	0%	0%	0%	41.62%
Controversies	0%	0%	0%	0.53%
Macro	0%	0%	0%	0%

Sep 29

ONC's price cleared key resistance with expanding volume, and the RSI is rising, but the short-term overbought level should be watched.
A Golden Cross has formed as the 50DMA crosses the 200DMA, turning the bias bullish, and confirmation is expected on rising MACD.
The MACD has made a bullish cross, and the price is holding above trendline support, indicating momentum favors higher targets.

Generated by AI

Community

Of the messages about ONC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	74.29%	51.47%	55.6%
Newcomers	100%	25.71%	48.53%	44.4%

Sep 29

Newcomers are focusing on the potential entry point for ONC after a pullback to the breakout level, with a suggested stop loss to manage risk.
The golden cross formed as the 50DMA crossed the 200DMA, turning the bias bullish, and confirmation is expected on the rising MACD.
ONC's price cleared key resistance with expanding volume, and the RSI is rising, but it's essential to watch for short-term overbought signals.

Generated by AI

BeOne Medicines

Social

Sep 29

Sentiment

Sep 2

Topics

Sep 29

Community

Sep 29

News

BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript

BeOne Medicines at Morgan Stanley conference: brukinsa, pipeline drive growth

BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal

BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

Also Discussed

BeOne Medicines Ltd. American Depositary Shares

Company Information

Location

News

BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript

BeOne Medicines at Morgan Stanley conference: brukinsa, pipeline drive growth

BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal

BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

Also Discussed

Social

Sep 29

Sentiment

Sep 2

Topics

Sep 29

Community

Sep 29